Not FDA cleared.

Not available in the United States.

HeartSciences’ MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device has been developed in response to the recent understanding that most forms of heart disease are associated with left ventricular (LV) relaxation abnormalities and left ventricular diastolic dysfunction (LVDD). The MyoVista wavECG Device uses wavelet signal processing to extract frequency information from the acquired ECG signal which is then analyzed using artificial intelligence. This breakthrough innovation uses proprietary technology that is designed to be used by physicians as part of an overall heart disease risk assessment to assist in determining whether a patient should receive further testing, evaluation and/or treatment.

The MyoVista wavECG Device is a 12-lead resting electrocardiograph (ECG) device that features wavECG Technology plus the capabilities of a full featured conventional 12-lead resting ECG including analysis using the University of Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The conventional ECG and MyoVista wavECG test results are independent.

HeartScience’s MyoVista wavECG Device benefits from years of research and development by HeartSciences to improve the ability of electrocardiography to detect most forms of heart disease. The MyoVista wavECG Device has a sensitivity of 85% and a specificity of 74%* for the detection of abnormal LV relaxation.

*Data on file at HeartSciences